Research peptide
Melanotan I 10 mg
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
Research peptide
Batch analytics · >99 % purity
Illustrative image; appearance and packaging may vary. 10 unlabelled vials, labelled only on the kit packaging. The selected strength applies.
Skin is not a passive coat. It reads light, processes signals and has its own messenger system made of peptide hormones. Right in the middle of this system sits Melanotan I, known internationally as afamelanotide and chemically as NDP-MSH: a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) made of 13 amino acids.
Its biological target is remarkably clear. Afamelanotide binds predominantly to the melanocortin-1 receptor (MC1R) on melanocytes and stimulates the formation of eumelanin there, the brown-black skin pigment (European product information on afamelanotide). This makes it possible to follow a single receptor pathway from signal to visible pigment.
Melanotan I, NDP-MSH and afamelanotide refer to the same active substance. The names come from different contexts: Melanotan I from peptide research, NDP-MSH from peptide nomenclature, afamelanotide from drug development. That helps with classification, because many misunderstandings arise purely from the variety of names.
Melanotan II is a separate matter. It is an independent, ring-shaped analog with a different receptor profile and not a variant of Melanotan I. Anyone who reads the two names side by side should treat them as two different molecules.
The MC1R belongs to the G-protein-coupled receptors. When it is activated, the concentration of cAMP in the melanocyte rises. This switches on the transcription factor MITF, which drives the pigment genes, including tyrosinase as the central enzyme of melanin synthesis.
What matters is which melanin is formed. Strong MC1R activation favors eumelanin, which is packaged into melanosomes and passed to surrounding keratinocytes. There it settles over the cell nucleus like an absorbing layer and distributes pigment across the epidermis.
| Property | Eumelanin | Pheomelanin |
|---|---|---|
| Hue | brown to black | yellow to reddish |
| Formation | favored by strong MC1R activation | favored by weak MC1R activation |
| Light behavior | broadly absorbing, photostable | less photostable under UV |
A rare metabolic disease shows that this pigment pathway can be medically relevant. In erythropoietic protoporphyria (EPP), the last enzyme of heme biosynthesis, ferrochelatase, has reduced activity. As a result, protoporphyrin IX accumulates, including in erythrocytes, plasma and skin.
Protoporphyrin IX is sensitive to light. Even brief exposure to visible light can trigger phototoxic reactions that manifest as burning pain, often within minutes. Visible skin changes are not necessarily present, which makes the disease hard to grasp in everyday life.
This is precisely where afamelanotide was studied clinically, in a specific formulation: an implant that releases the active substance continuously. The European authorization covers the prevention of phototoxic reactions in adults with EPP; the US approval covers extended pain-free light exposure in adults with EPP-associated phototoxic reactions (US approval documents for Scenesse). This classification applies to the tested implant.
Two randomized, placebo-controlled trials studied the formulation in adults with EPP, one in Europe with 74 and one in the United States with 94 participants. The measure recorded was cumulative pain-free time in direct sunlight over the entire observation period, not a value per day (randomized afamelanotide trials in EPP).
In the US trial, the median over six months was 69.4 hours with afamelanotide versus 40.8 hours with placebo. In the European trial, the median over nine months was 6.0 versus 0.8 hours. The protocols differ, so the figures are not directly comparable with one another.
In addition to light time, disease-specific quality of life improved in the trials. The findings apply to adults with EPP, to the implant studied and to the respective observation conditions; they cannot be transferred to healthy skin or other photodermatoses. These data are not linked to a cosmetic tanning indication.
What makes Melanotan I interesting for research is the clarity of the model: a peptide of 13 amino acids, one predominantly engaged receptor, a well-described pathway through to pigment. Anyone investigating pigment biology, MC1R signaling pathways or the role of eumelanin finds a manageable and well-documented starting point here.
Melanotan I 10 mg contains an active substance amount of 10 mg per vial; the MT-1 10 mg variant can be selected directly in the shop. The figure refers to the mass of the contents, not a concentration and not an amount for use. Buy Melanotan I 10 mg now and view the variant in the shop.
No reviews yet. Be the first to share your experience.
Research Use Only (RUO)
Tier I · Synthesis QC
Tier I · Synthesis QC
In-house · per step
RP-HPLC, MS confirmation, sequence verification in cleanroom.
Tier II · In-process
953
satisfied
99.41%
Avg. purity 2026
4.8 ★
Store rating
Tier II · In-process
Batch · final
Identity, purity, and assay before release.
Tier III · Third-party lab
Tier III · Third-party lab
External · independent
HPLC, ICP-MS, and microbiology by accredited lab.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.41% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
Yes. Melanotan I, NDP-MSH and afamelanotide designate the same synthetic active substance, an analog of alpha-MSH made of 13 amino acids.
Melanotan II is a separate, ring-shaped analog with a different receptor profile. The two substances are not variants of one another and are considered separately in research.
The MC1R sits on melanocytes and controls the formation of eumelanin. Afamelanotide acts primarily at this receptor, which shapes its pigment-biology profile; this is not meant to imply exclusive receptor binding.
What was recorded was pain-free time in direct sunlight over the entire observation period: six months in the US trial and nine months in the European trial. The figures are totals, not a daily exposure duration.
It designates the active substance amount per vial. It is neither a concentration nor information on use or dosage.